ADXN

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-86.2K ExitQ2 2025 $86k -- $6.82
Ken GriffinCitadel Advisors $1.6K AddQ1 2025 $1.6k -- $6.82

News

globenewswire.comAddex Convenes Annual General Meeting 2026globenewswire.comJun 5

seekingalpha.comAddex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcriptseekingalpha.comApr 30

globenewswire.comAddex Reports Full Year 2025 Financial Results and Provides Corporate Updateglobenewswire.comApr 30

globenewswire.comAddex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Modelglobenewswire.comApr 29

globenewswire.comAddex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Modelglobenewswire.comApr 21

Trade ADXN

About Addex Therapeutics Ltd

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.

CEO: Timothy Mark Dyer
IPO Date: Feb 12, 2020

Market Data

Open: $6.50
High: $6.50
Low: $5.98
Volume: 2.9K
Avg Volume: 4.6K
52W High: $12.05
52W Low: $5.41

Valuation

Market Cap: $4.5M
Enterprise Value: $5.4M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-2.1M
Revenue: $30k
Net Income: $-6.7M
Cash: $1.6M
Debt: $35k

Events

EarningsAug 24